Tuesday, December 24, 2019 4:35:51 AM
BXDX Meloxicam IV formulation incorporates ALKS Nanocrystal technology
Recent ALKS News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/27/2024 09:33:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2024 09:22:05 PM
- Alkermes to Participate in Upcoming Investor Conferences • PR Newswire (US) • 11/25/2024 09:00:00 PM
- Alkermes to Participate in Upcoming Investor Conferences • PR Newswire (US) • 11/25/2024 09:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/12/2024 09:48:15 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/12/2024 09:15:19 PM
- Alkermes to Participate in Two Upcoming Investor Conferences • PR Newswire (US) • 11/11/2024 09:00:00 PM
- Alkermes to Participate in Two Upcoming Investor Conferences • PR Newswire (US) • 11/11/2024 09:00:00 PM
- Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences • PR Newswire (US) • 11/07/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/07/2024 12:47:26 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/24/2024 01:15:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2024 11:05:11 AM
- Alkermes plc Reports Third Quarter 2024 Financial Results • PR Newswire (US) • 10/24/2024 11:00:00 AM
- Alkermes plc Reports Third Quarter 2024 Financial Results • PR Newswire (US) • 10/24/2024 11:00:00 AM
- Alkermes to Report Third Quarter Financial Results on October 24, 2024 • PR Newswire (US) • 10/17/2024 08:00:00 PM
- Alkermes to Report Third Quarter Financial Results on October 24, 2024 • PR Newswire (US) • 10/17/2024 08:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/09/2024 08:07:13 PM
- Alkermes to Host Investor Event to Review Orexin Portfolio Strategy • PR Newswire (US) • 09/25/2024 12:00:00 PM
- Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024 • PR Newswire (US) • 09/23/2024 11:00:00 AM
- Alkermes to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference • PR Newswire (US) • 09/19/2024 08:00:00 PM
- Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program • PR Newswire (US) • 09/13/2024 11:00:00 AM
- Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program • PR Newswire (US) • 09/13/2024 11:00:00 AM
- Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference • PR Newswire (US) • 08/28/2024 08:00:00 PM
- Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference • PR Newswire (US) • 08/28/2024 08:00:00 PM
- Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2 • PR Newswire (US) • 08/22/2024 11:00:00 AM
North Bay Resources Commences Fran Gold Winter Ore Shipment to Bishop Gold Mill, California • NBRI • Dec 2, 2024 9:07 AM
VAYK Reached Agreement on Terms to Acquire $1 Million Company for Disruptive Airbnb Strategy • VAYK • Dec 2, 2024 9:00 AM
ILUS Announces Completion of QIND Acquisition by Fusion Fuel (NASDAQ: HTOO) • ILUS • Nov 27, 2024 12:35 PM
Cannabix Technologies Receives Positive Testing Certification for Breath Logix Autonomous Alcohol Breathalyzer • BLO • Nov 26, 2024 8:48 AM
BioQuest, Inc. and BotMakers Expand AI Marketing Services with SpeedLeads XL and MarketScope XL. Bioquest Corp. and BotMakers, Inc. are Partnered to Expand AI Marketing Services with SpeedLead XL and MarketScope XL • BQST • Nov 26, 2024 8:00 AM
BNCM Announces its Q3 and 9-Month Growth Results for 2024 • BNCM • Nov 26, 2024 7:03 AM